The global dialysis market is expected to reach $118.51 billion by 2023 from $91 billion in 2017, registering a CAGR of 4.4% from 2018 to 2023.
Increase in government funding for dialysis, rise in incidence of hypertension & diabetes, surge in the number of ESRD patients, and dearth of kidney donors drive the growth of the market. However, product recalls and health risks & complications associated with dialysis hamper the growth of the market. On the other hand, technological advancements and growing inclination toward home peritoneal dialysis treatment would create new pathways to the market players in future.
Hemodialysis segment to remain dominant throughout 2023
Hemodialysis segment contributed nearly nine-tenths share of the total market revenue in 2017 and is expected to remain dominant throughout the forecast period. This is attributed to technological advancements in the medical sector, proliferation of dialysis centers, and increase in prevalence of chronic conditions among the geriatric population. However, the peritoneal dialysis segment would grow at the fastest CAGR of 6.1% from 2018 to 2023, owing to simplicity of the procedure, reduced need for trained medical staff, and minimal requirement for technical support & electricity.
In-center dialysis segment to retain lion‘s sharethrough 2023
In-center dialysis segment accounted for nearly 85% of the total market revenue in 2017 and is projected to maintain its lead through 2023. This is due to the presence of a large number of dialysis centers and availability of skilled workforce & advanced equipment at these centers. However, the home dialysis segment is expected to register the highest CAGR of 7.0% from 2018 to 2023, owing to the ease & convenience offered by these services, high preference among patients, and advancements in technologies related to home dialysis equipment.
North America to maintain its dominance by 2023
North America accounted for nearly three-fifths of the total market revenue in 2017 and is expected to maintain its lead throughout 2023, owing to the high prevalence of hypertension & diabetes, increase in disposable income, and high adoption rate of technologically advanced products in the region. However, Asia-Pacific would witness the highest CAGR of 7.9% from 2018 to 2023, owing to surge in incidence of kidney disorders, increase in healthcare expenditure, and low rate of organ transplantation.
The key market players analyzed in the study are Fresenius Medical Care AG & Co. KGaA, DaVita Inc., Baxter International, Inc., B. Braun Avitum AG, Nipro Corporation, Nikkiso Co. Ltd., Diaverum Deutschland GmbH., Asahi Kasei Corporation, NxStage Medical, Inc., and Medicators, Inc. These players have implemented various strategies such as partnerships, mergers & acquisitions, expansions, collaborations, joint ventures, and others to gain a stronghold in the market.
Web:https://www.alliedmarketresearch.com
Follow Us on LinkedIn:https://www.linkedin.com/company/allied-market-research
0 Comments